NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis

Exclusion Criteria

• •Clinical or radiological or laboratory evidence of current infectious disease (temperature \>38°C, elevated CRP \>5mg/dl, leukocytosis \>11400, elevated neutrophiles)
• •antifungal therapy within 8 weeks prior to inclusion
• •immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc)
• •active haematooncological diseases
• •HIV positivity
• •ad 2:
• •glucocorticoid treatment with prednisone equivalent of ≥20mg/d
• •inherited neutrophil deficiency
• •absolute neutrophil count of ≤500cells/mm3
• •antifungal therapy within 8 weeks prior to inclusion
• •immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc)
• •active hematooncological disease
• •HIV positivity
• •ad 3:
• •Antifungal therapy within 8 weeks prior to inclusion
• •immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d, methotrexate, azathioprin etc)
• •active hematooncological disease HIV positivity
• •ad 4:
• •Clinical or radiological or laboratory evidence of current infectious disease (temperature \>38°C, elevated CRP \>5mg/dl, leukocytosis \>11400, elevated neutrophiles)
• •antifungal therapy within 8 weeks prior to inclusion
• •immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc)
• •active haematooncological diseases
• •HIV positivity